BioSpace News Archive

Actinium Pharmaceuticals, Inc. today announced that the positive results from the pivotal Phase 3 SIERRA Trial of Iomab-B were presented in an oral presentation at the European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting that was held in Paris, France April 23 – 26, 2023.

Defence Therapeutics Inc. (CSE: DTC) (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted registration for its trademark DEFENCE THERAPEUTICS®.

NuVasive, Inc. (NASDAQ: NUVA) today announced that at the special meeting of shareholders held earlier today, its shareholders voted to approve the adoption of the Company’s merger agreement with Globus Medical (NYSE: GMED).

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (“BioHarvest” or the “company”) has announced that its VINIA partnership with House of Athlete trainer Yo Murphy has resulted in several of his high-profile players entering the NFL draft as members of “Team VINIA.”

The Insight Partners published latest research report on “Antibiotics Market Share Report, Size, Trends, Growth & Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Class; Action Mechanism, and Geography” the global market size was valued at USD 44,111.31 million in 2020 and is projected to reach USD 59,253.24 million in 2028; it is expected to grow at a CAGR of 4% during 2021–2028.

BioInvent International The Annual General Meeting of BioInvent International AB resolved to elect Erik Esveld as new Board member, to re-elect the Board members Natalie Berner, Kristoffer Bissessar, Thomas Hecht, Leonard Kruimer, Nanna Lüneborg, Vincent Ossipow and Bernd Seizinger and to implement a long-term incentive program.

ProCure Proton Therapy Center welcomes Timothy H. Chen, MD, to a growing list of tri-state physicians with expertise in treating cancer patients with proton therapy.

CinRx Pharma today announced that the first study participant has been dosed in CinDome Pharma’s Phase 2 envision3D study of deudomperidone (CIN-102) in patients with diabetic gastroparesis.

Seagen Inc. (Nasdaq:SGEN) (Seagen or the Company) reported financial results today for the first quarter ended March 31, 2023.

Aytu BioPharma, Inc. received U.S. Food & Drug Administration (“FDA”) approval of the Adzenys XR-ODT® (“Adzenys”) Prior Approval Supplement (“PAS”).